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ba r h osiuinlpmlctosfrdu
On September 27, 2011 the UC Berkeley College
Republicans hosted a bake sale that was splashedqucladnigintefldogntcsndt
across headlines.' This sensational bake salebenusdtdigoeadratlnse- h
had a slightly different pricing scheme from the sol opn erqie od opoei
average bake sale: prices ranged from two dollars atosps osiuinlmse fi ihst
for white men to twenty-five cents for Native
Americans.2 If you were not in attendance for theF
uproar leading up to the day of Berkeley's "pay-torgleinawyhtecuaesomne
by-race" bake sale,3 the pricing scheme may not t xado e cetfcdsoeiswien
elicit too much emotion; however, what if that dpiigcranptet flf-aigtete
were the case when you went to the pharmacy?4 hnetramtisbedoterrc?1
Imagine hearing about a medication for a disease Teie fdfeetrca aeoish
you have. You go to your physician to see if this
may be a glimmer of hope for your ailment, onlygandfolokgateeicvrneshw
to feel offended. Upset and outraged, you wantcrs-ailimaiteandfeecs.1A
an explanation as you learn your physician can avne r aei cec hog h s
prescribe the drug, but since you are not black, o eeis efietfal lsiiain r
you may have to pay more.' Further inquiry lsn hi tlt nmdcn.1 o xml
reveals black patients may pay less because the
drug was approved for use in black patients with
heart failure. 6 as a efudi epeo eiernan
As unsettling as it may sound, that is the caseIninogn.1
if you are Caucasian, Asian, Pacific Islander,Th adncsmeuiggnererc
or any other race besides black, and wouldarledntomicinrgmnsht i
1
like to try BiDil.7 Naturally, the situation csoie oa niiulsgntcmku.
demands explanation when the Food and Drug Gntc sbigue oaayehwa
Administration (FDA) approves a drug for useinvdulrattomicinsna eti
in a particular racial group. In light of advances lvl 6Gntc a h olta loe
in genetic science, should a company havedotrtoieifthall, L-350
to provide evidence as to why it thinks it is wihcue eiu des ecint h
appropriate to make a drug race specific? What du bcvri oeptet.1 o ain
University sh ngton CaegelofkLaw1She receikv
er~~Aaav1 Ahi fromthesnivesityofo oria. S oiscurrnto
a~~proaie notene"1 andcomen eitodfrv ddmiisratveLa
Review.rSheiwouod ikeitonthankeProfessorsnobert G
thankkowede her faibycouisgiperSr.,efrtbeig an nd es
are ther constitutionalwilicfaonfi for u
qu ispcklybadandintermfienfgenheticsandeiti
bresing.us eoaioeadretiln ssy es;dwo,
shudacmpn erqurdtGo opoei
cinpascntttoalmserfi i st
1s aetItre eiiet fisdrg nta
The idao jifrn aca aeoish
reeie stogciiim.U h nomto
gandforokn tgntcvracsso
cros-racal imilrites ad difernces121































out B. Genetic Focused Approach to Persor
are, The study of Pharmacogenomics (PG>
the (PGt) is the crux of the concept that p(
Bber provide precision in treating disease. 5
hen differently by diseases and can react t
n), multitude of reasons. 56 Genetics can caust
lized

























































































. What Goes into Getting a Drug
































































































































tting the Fifth Amendment









































































rescription payment when a doctor prescribes a medication to a BScat
?atient for the intended use.141 Many times, an insurance companyMayeprsckolddthtaeisoilycntutd.
nay not reimburse for experimental or investigational drugs, whichThpoiontknstatrcisaolialytegoungepl
nay include off-label uses, because of the policy that insurance is forsoilybednivntdctra.18Phpsoitlisusn
FDA-approved care. 142 If an insurance company will not reimburse otietesoeo h D' uve;hwvr h D hu
in unapproved race using a race-specific drug, then a government ke hmi idwe aigdcsosadntalwrc ob
iction has caused an individual to pay more based on their race.143 ue sasotu oudrtnigbooyadgntc ndu
;ot only has a government action caused the individual to be treatedaprvl.11EethHathndumnSvis prmn
lifferently, but the individual has also been forced to pay more fordrfearpotsknthFDtoncugeee-sdsuis v
3omething on account of race which amounts to a deprivation Ofraebsdos.10Teanristtalwngac-sd htut
?roperty. 144 The deprivation of property and race-based differentialgiecrdnetthieaorc-bsdiessorru.16
reatment implicates the equal protection component of the FifthSoecicsf xsathtoomhfcuongeiswl
Amendment. 145 iicniiesceyfofiigptniludrygise.16
Che Fifth Amendment is also applicable to actions taken by the Te erta nta ffxn aayi atr uhaitrai
federal government. 146 The Amendment states "No person shall scaeooiadevrnetlieulteteslto i
. . be deprived of life, liberty, or property, without due process b osl xesv rg.13Frisacasuycnutdi
f law."147 In Bolling v. Sharpe, 148 the Supreme Court held that,PuroRcshwdaoretinihhghytlcbod esn
Ilthough the Fifth Amendment did not have an Equal Protection(S3)soi-cnmctaundknclr.14IPetoRo
l.ause like the Fourteenth Amendment, the concepts of Due Processdifrnskntesadaclfaueshvdfeet lta
ind Equal Protection were not mutually exclusive. 149 In Bolling, aclsicaon.15hlgtetkntnsarcledbnomiu
ase about segregation in public schools in the District of Columbia,skntesaecld rgnindaksinoesreale
he Court discussed the limits that the Fifth Amendment's Due 16
Process clause places on race-based policymnaking: erhathhiesSBanblcolsifainhdtelws
Liberty under law extends to the full range of conduct which asscoenmistusnraed16Thrslsidctd a
the individual is free to pursue, and it cannot be restricted soienmcadcutrlftrsreotlklyheupiso
except for a proper governmental objective. Segregation thdiprt.18Polatheowrndftescealpcru
in public education is not reasonably related to any proper d o xeinea aysrsosfo aea epea h
governmental objective, and thus it imposes on Negro hihredotescealpcru.19Cnnosexsret
children of the District of Columbia a burden that constitutes pesrsfo aimcnrsl nhg lo rsuea ela
an arbitrary deprivation of their liberty in violation of the Due ohrcrivsua ecin.10A nrae ou ngntc
Process Clause. 150 wl o edt h fet fohrfcos nti aeclua
rxguably, the government has a proper objective in improving thecuefrteulrapobm.Frxmlgntirsachedt
realth of the group the drug is approved for; however, if the head OfthfidntatsclcelwsotxluveoArcn sednt
he FDA is acting within the scope of power granted, a court could adta h ri rtcsaantmlra eaieevrnet
inalyze whether the action taken was arbitrary, capnicious, or anfatr17
ibuse of discretion. 151 It could be contended that without requiring
i drug company seeking to get a race-based drug approved to show
t exhausted all other possible alternatives to race, the approval isWhnteFAidalgwthrc-pifcruapovleqss
irbitrary and capricious. 152 Since the Supreme Court has given i hc ersetv nlsssostedu ae etri n
:uidelines on how to constitutionally use race, the FDA should--41-41- TNA-- lA41-A-4-- -
pr anidvdalo rprt ihu apoeovrmna
bjctve15 Dbaabyaproin arae- e fcpru aplcaio
o 1mrv h elho n rupa h xes fohr a
lot e a rope govrnmetalobjetivesinc it s brdesm
nrbirrl treasteecue rousufilnvoaino
B.Soia mpictin
Thgpstintae irha rc1i pltia syte gruigrep
1kge1 1hmi idwe aigdcsosadntalwrc ob
usda1asotutt1ndrtnin iloyadgeeis ndu
diineniiz scit fro piigptniludrynsus1
Thyfa1htisedo iigctayi atr uhaitrai
soilJcnmc n niomnalieulteteslto i
betlelepesvbrg.13Frisane tdrcnutdi
PuroRc1hwe orlto wt ihssoicbodpesr
1SPs oeooi tts n knclr14I uroRc
difrnrki oe njfca etreraedfern utr
clsiiain.65Telgts ki oe rkale lno eir
skntnsaeclerrgeladdr kntnsaecle
ner.6ph td on htpepewt h lsiiaino
nerparh igetSPadbano asfctonhdtelws
asspoeoomcsau ncesd17Thpeutrndctdta
socoeonmi ad ulura fctrsar mstliklyth clpit 0
wilntlaroteefet fohrfcori hscs utra
eldnroit pt1 nepniedrgsadn nsusiuina
1uefrtecutrlpole1Freaplgntcre1rhl t
th fndngthtsikl cllwa otexluiv t frca dscndn
apriciousl approved for use sole
'nake race-basea approvals because to do otherwise may
stitutional challenges. Expanding the scope of safety will
FDA to prove its decisions for approving a race-specific
not made arbitrarily or capriciously. Furthermore, car
atinizing race-based approvals is also socially responsit
1 , when the FDA came out with its guidance on PGx, it lh
r open for race-based shortcuts by encouraging the coll(
3Gx data but not requiring it for race-based approvals. Wi
1 approval of Inform Dual ISH test and advances being
he field of PGx and PGt, it is time the FDA closed the di
" Id t 173
Id)
PrgotcIuiaocnUeieSrosA ilr acr 9 M .o
O6 wms&GNCLG 1,86(06 Tphn DteTS SO
std6 oecriaigbc n ht wrinwt trn eospp r
cace anth vrxrsso fH R/e}
7oCfi
" Id,
14 eA daadCntutr.Ic .Pn.55US 0,20(95 h igta
